ASH Annual Meeting and Exposition | Conference

RARα Agonist SY-1425/Azacitidine Shows Clinical Activity in Heavily Pretreated Relapsed/Refractory AML

December 6th 2020

A novel combination comprised of the oral, selective RARα agonist SY-1425 and azacitidine demonstrated clinical activity with acceptable tolerability in a heavily pretreated population of patients with relapsed/refractory acute myeloid leukemia with RARA positivity.

Novel CAR Engineering Overcomes Resistance in Large B-Cell Lymphoma With CD58 Loss

December 5th 2020

December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.

Off-the-Shelf, SARS-CoV-2-Specific T Cells Display Antiviral Activity

December 5th 2020

The effector profile of the SARS-CoV-2 virus–specific T-cell therapy, ALVR109, was polyclonal, polyfunctional, and displayed cytolytic activity against viral targets without allogeneic or autologous reactivity, suggesting ALVR109 could be a safe and effective treatment for the coronavirus disease 2019.

Anti-ICOS Antibody MEDI-570 Elicits Durable Responses in Relapsed/Refractory T-cell Lymphomas

December 5th 2020

The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma

December 5th 2020

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

First-in-Human Trial Demonstrates Clinical Activity With ROR1-Directed ADC in MCL and DLBCL

December 5th 2020

December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

bb21217 Continues to Showcase Durable Responses in Multiple Myeloma

December 5th 2020

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

December 5th 2020

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.

Dr. Verstovsek on the Results of the PV-AIM trial in Polycythemia Vera

December 5th 2020

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

Dr. Wierda on the Results of the CAPTIVATE Trial in CLL and SLL

December 5th 2020

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Survival Benefit of Venetoclax and Rituximab in Relapsed/Refractory CLL Persists Out to Five Years

December 5th 2020

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.

Axi-Cel Elicits 92% ORR in Indolent Non-Hodgkin Lymphoma

December 5th 2020

December 5, 2020 - Axicabtagene ciloleucel demonstrated high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

Continued Ibrutinib, Post Fixed-Duration of Ibrutinib/Venetoclax, Elicits Similar 1-Year DFS Vs Placebo in CLL/SLL

December 5th 2020

December 5, 2020 - Patients with previously untreated chronic lymphocytic leukemia /small lymphocytic lymphoma who received a placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease.

Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple Myeloma

December 5th 2020

December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.

Axi-Cel Elicits Long-Term Disease Control in Large B-Cell Lymphoma

December 5th 2020

December 5, 2020 - The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

Momelotinib Sustains Long-Term Survival in Patients With Myelofibrosis

December 5th 2020

December 5, 2020 - Momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.

High-Dose Imetelstat Improves Overall Survival and Offers Clinical Benefits in High-Risk Myelofibrosis

December 5th 2020

December 5, 2020 - Patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors saw better overall survival, spleen response, and symptom response with higher doses of the telomerase inhibitor imetelstat.

Racial and Ethnic Related Socioeconomic Disparities Influence Survival Outcomes in AML

December 5th 2020

December 5, 2020 - Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.

Selinexor Shows Clinical Benefit Across Age Groups in Relapsed/Refractory DLBCL

December 5th 2020

December 5, 2020 - Selinexor demonstrated a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma, regardless of age.

Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis

December 5th 2020

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.